Claim Missing Document
Check
Articles

Found 6 Documents
Search
Journal : Bioscientia Medicina : Journal of Biomedicine and Translational Research

Investigating the Landscape of Programmed Death-Ligand 1 (PD-L1) in Thymic Tumors: Implications for Histopathological Classification and Staging Rio Hendra; Noza Hilbertina; Henny Mulyani; Tofrizal; Afriani; Husna Yetti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 7 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i7.1338

Abstract

Background: Thymic epithelial tumors (TETs) are uncommon malignancies originating in the mediastinum, characterized by considerable histopathological diversity and variable clinical trajectories. Programmed Death-Ligand 1 (PD-L1), an immune checkpoint protein, is implicated in mechanisms of tumor immune evasion. This study aimed to investigate the correlation between PD-L1 immunoexpression and distinct histopathological types, as well as the Masaoka-Koga stage, in TETs. Methods: This cross-sectional investigation analyzed 29 archival cases of TETs diagnosed between January 2019 and December 2024 at the Anatomical Pathology Laboratory of Dr. M. Djamil General Hospital Padang. Samples were procured via consecutive sampling from formalin-fixed paraffin-embedded (FFPE) tumor tissues. Histopathological classification was reassessed according to the WHO 2021 criteria. PD-L1 expression was evaluated immunohistochemically and quantified using the Tumor Proportion Score (TPS). Masaoka-Koga staging was determined from clinical records. Statistical analysis of correlations was performed using the Chi-square test. Results: PD-L1 immunoexpression was detected in the preponderance of cases. Low positive PD-L1 expression (TPS 1-49%) was observed in 82.8% of TETs, while high positive expression (TPS ≥50%) was noted in 10.3%. Thymic carcinoma constituted the most prevalent histopathological category (51.7%), and the majority of patients (91.7%) presented at an advanced Masaoka-Koga stage. Statistical analysis did not demonstrate a significant correlation between PD-L1 expression levels and histopathological type (p=0.195). Furthermore, no significant association was identified between PD-L1 expression and Masaoka-Koga stage (p=0.800). Conclusion: This study indicated that while PD-L1 is frequently expressed in TETs within this cohort, its expression level did not exhibit a significant correlation with specific histopathological subtypes or the Masaoka-Koga clinical stage. Further investigations incorporating larger sample sizes are warranted to delineate the precise role of PD-L1 within the complex biological spectrum of thymic neoplasms.
Unraveling the Angiogenic Landscape in Endometrioid Endometrial Carcinoma: VEGF Expression, Histopathological Differentiation, and Lymphovascular Invasion as Key Players Mustika Sari; Aswiyanti Asri; Tofrizal; Henny Mulyani; Syamel Muhammad; Husna Yetti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 7 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i7.1340

Abstract

Background: Endometrioid endometrial carcinoma (EEC) is a prevalent gynecological malignancy whose prognosis is influenced by factors including histopathological grade and lymphovascular invasion (LVI). Angiogenesis, crucial for tumor growth and metastasis, is significantly mediated by vascular endothelial growth factor (VEGF). This study aimed to investigate the expression of VEGF in EEC and its correlation with histopathological differentiation and LVI. Methods: This observational analytical study employed a cross-sectional design using 36 archival paraffin block samples of EEC diagnosed between January 2022 and December 2024 at the Anatomical Pathology Laboratory of Dr. M. Djamil General Hospital Padang. Cases were selected via simple random sampling from a population of 59. Histopathological grade (Grade 1, 2, or 3 based on FIGO architectural and nuclear criteria) and LVI (negative, focal, or substantial) were re-evaluated from Hematoxylin-Eosin (H&E) stained slides. VEGF expression was assessed by immunohistochemistry, scored semiquantitatively based on the percentage of positive tumor cells and staining intensity, and categorized as low or high. Data were analyzed using Chi-square tests, with p<0.05 considered statistically significant. Results: The mean age of patients was 54.36 years, with the highest prevalence in the 51-60 age group (41.7%). Grade 3 tumors were most common (38.9%), followed by Grade 2 (33.3%) and Grade 1 (27.8%). LVI was present in 47.2% of cases, predominantly focal (38.9%). High VEGF expression was observed in 58.3% of EEC cases. A statistically significant association was found between high VEGF expression and higher histopathological grade (p=0.000), with 66.7% of Grade 3 tumors showing high VEGF expression. No significant association was found between VEGF expression and LVI (p=0.080). Conclusion: High VEGF expression significantly correlated with higher histopathological grades in EEC, suggesting its role in tumor aggressiveness and dedifferentiation. However, a significant association with LVI was not established in this cohort. VEGF expression warrants further investigation as a potential prognostic biomarker and therapeutic target in EEC.
p63 Expression in Ductal Carcinoma In Situ (DCIS) of the Breast and Its Correlation with Histopathological Grading and Morphological Variants Runky Pebranka; Aswiyanti Asri; Tofrizal
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i1.1178

Abstract

Background: Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer with varying potential for progression to invasive carcinoma. Myoepithelial cells (MECs) play a role in preventing this progression, and their absence is a hallmark of invasive disease. The p63 protein is a myoepithelial marker that can be assessed by immunohistochemistry (IHC). This study aimed to evaluate the relationship between p63 expression in MECs, the grade of DCIS, and the morphological subtype of DCIS. Methods: A cross-sectional study was conducted on 35 cases of DCIS diagnosed at the Anatomical Pathology Laboratory of Dr. M. Djamil General Hospital Padang. Paraffin blocks were collected, and Hematoxylin and Eosin (H&E) slides were reviewed to confirm the diagnosis and determine the histopathological grading (low, intermediate, and high) and morphological variants (comedo and non-comedo) of DCIS. Paraffin blocks were re-cut for p63 immunohistochemical staining. The extent of p63 expression was classified as complete or incomplete. Results: The majority of DCIS cases were high grade (54.3%) and of the non-comedo subtype (68.4%). All cases with complete p63 expression were of low histologic grade, while all cases with incomplete p63 expression were of high histologic grade. The results of the Chi-square test showed a statistically significant relationship between p63 expression and histopathological grading (p<0.001). There was no statistically significant relationship between p63 expression and morphological variant. Conclusion: The absence of p63 expression in DCIS is associated with high histologic grade. This finding suggests that p63 IHC may be a useful adjunct in evaluating DCIS.
The Significance of TGF-β Expression in Predicting Lymphovascular Invasion and Lymph Node Metastasis in Colorectal Cancer Aini, Julpa Nurul; Aswiyanti Asri; Noza Hilbertina; Tofrizal; Avit Suchitra; Husna Yetti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i1.1182

Abstract

Background: Colorectal cancer (CRC) is a major health burden globally. The prognosis of CRC is strongly influenced by the presence of lymphovascular invasion (LVI) and lymph node (LN) metastasis. Transforming growth factor-beta (TGF-β) is a cytokine with a complex role in CRC progression. This study aimed to evaluate the significance of TGF-β expression in predicting LVI and LN metastasis in CRC. Methods: This cross-sectional study involved 50 patients diagnosed with CRC. The expression of TGF-β was assessed using immunohistochemical staining and the Allred scoring system. The relationship between TGF-β expression and the presence of LVI and LN metastasis was analyzed using the Chi-square test. Results: High TGF-β expression was significantly associated with both LVI (p = 0.011) and LN metastasis (p = 0.012) in CRC. Patients with high TGF-β expression had a higher risk of LVI and LN metastasis compared to those with low TGF-β expression. Conclusion: TGF-β expression is a significant predictor of LVI and LN metastasis in CRC. This finding has potential implications for risk stratification and treatment decisions in CRC patients.
Primary Malignant Peritoneal Mesothelioma Mimicking Ovarian Carcinoma: A Case Report Highlighting the Importance of Immunohistochemistry Rio Hendra; Tofrizal; Hera Novianti; Yessy Setiawati
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 3 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i3.1212

Abstract

Background: Primary malignant peritoneal mesothelioma (PMPM) is an uncommon and aggressive malignancy arising from the mesothelial lining of the peritoneal cavity. The diagnosis of PMPM is often challenging due to its rarity, nonspecific clinical presentation, and histologic similarities to other malignancies, particularly adenocarcinomas. Immunohistochemistry plays a crucial role in differentiating PMPM from metastatic adenocarcinoma, which is essential for accurate diagnosis, appropriate treatment, and prognostication. Case presentation: We present the case of a 43-year-old female who presented with abdominal distension, ascites, and weight loss, initially raising suspicion of ovarian carcinoma. However, histopathological examination of the omental tissue revealed a proliferation of epithelial cells with papillary and glandular-like growth patterns. Immunohistochemical staining demonstrated strong positivity for calretinin, a mesothelial marker, while staining for estrogen receptor (ER) and progesterone receptor (PR) was negative, effectively ruling out an ovarian or endometrial origin. The diagnosis of PMPM, epithelioid subtype, was confirmed. Conclusion: This case underscores the challenges in diagnosing PMPM and highlights the critical role of immunohistochemistry in differentiating it from metastatic adenocarcinoma. Accurate diagnosis is essential for determining appropriate management strategies and providing prognostic information.
Loss of E-cadherin Expression Stratifies Aggressive versus Non-Aggressive Papillary Thyroid Carcinoma Dwi Yanti Fioni Putri; Yenita; Aswiyanti Asri; Tofrizal; Rony Rustam; Husna Yetti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i2.1498

Abstract

Background: Papillary thyroid carcinoma (PTC) is generally indolent, yet specific histological subtypes defined by the World Health Organization (WHO) are linked to aggressive behavior and poor prognosis. The loss of the cell-adhesion protein E-cadherin is a hallmark of the epithelial-to-mesenchymal transition (EMT), a process implicated in tumor aggression. However, its role in stratifying PTC subtypes versus its correlation with tumor stage remains a significant controversy in the literature. This study aimed to disentangle these two parameters by clarifying the relationship between E-cadherin expression and both histological phenotype and tumor stage. Methods: This was an observational, cross-sectional pilot study on 40 randomly selected, formalin-fixed, paraffin-embedded (FFPE) PTC cases from a 2024 cohort (N=74) at a tertiary hospital in Indonesia. All cases were re-evaluated and classified according to the WHO 5th Edition (2022) criteria as non-aggressive (n=34) or aggressive (n=6). E-cadherin expression was assessed by immunohistochemistry (IHC) using a standardized semi-quantitative scoring system (product of intensity and proportion) adapted from previous studies, with inter-rater reliability assessed (Cohen’s Kappa = 0.88). Scores were dichotomized as 'High' (n=25) or 'Low' (n=15). The association between E-cadherin expression and both histological subtype and AJCC 8th Edition tumor stage (Early: I/II [n=32] vs. Advanced: III/IV [n=8]) was analyzed using Fisher's Exact Test, with Odds Ratios (OR) and 95% Confidence Intervals (CI) calculated. Results: High E-cadherin expression was observed in 62.5% of cases. A statistically significant and strong association was found between E-cadherin expression and histological subtype (p=0.021; OR 12.0; 95% CI 1.2–118.9). Low E-cadherin expression was present in 83.3% (5 of 6) of aggressive-subtype tumors, versus only 29.4% (10 of 34) of non-aggressive subtypes. In contrast, no significant correlation was found between E-cadherin expression and advanced tumor stage (p=0.126; OR 3.67; 95% CI 0.7–18.6). Conclusion: Loss of E-cadherin expression is a significant biomarker associated with high-risk, aggressive histological phenotypes in PTC. Its lack of correlation with tumor stage, confirmed by an uncertain OR, suggests E-cadherin's role is indicative of an inherent tumor biological phenotype (aggressiveness) rather than a linear marker of tumor progression (stage). This dichotomy, likely reflecting EMT/MET plasticity, positions E-cadherin IHC as a powerful ancillary tool for pathological risk stratification.
Co-Authors Abdiana Abdiana, Abdiana Afdal Afdal Afriani Afriani, Nita Aini, Julpa Nurul Aizah, Havina Nurul Aljassri, Resti Karunia Alvarino Alvarino Amel Yanis Aqilah, Giffary Zahida Ariani, Novita Ariani, Yuliza Arnofyan, Budi Pratama Asri, Ennesta Aswiyanti Asri Aswiyanti Asri Athika Rahmawati Avit Suchitra Azmal, Nita Afriani Cimi Ilmiawati, Cimi Daan Khambri Deddy Saputra Deddy Satriya Putra Desmawati Desmawati Dessy Arisanty Devianti, Loli Djong Hon Tjong Dwi Yanti Fioni Putri Dwisari Dillasamola Elli Firdamila Elmatris Elmatris Elmatris, Elmatris Endrinaldi Ennesta Asri Erkadius Erkadius Eryati Darwin Eryati Darwin Eti Yerizel Fadhilah, Maisarah Fadil Oenzil Fadillah Fadillah Fajriza Yona Fesdia Sari Firdamila, Elli Gardenia Akhyar Gusti Revilla Hafni Bachtiar Handriyani, Fitri Nur Hasmiwati Henny Mulyani henny Mulyani Hera Novianti Hirowati Ali, Hirowati Husna Yetti Husna Yetti Intan, Shinta Ayu Khotimah, Rifqoh Kusumardani, Dini Lubis M Mahata, Liganda Endo Maliza, Rita Mayorita, Pamelia Miftah Irramah Muhammad Idris Muhammad Nazri Janra Mustika Sari Naqia, Masyithah Nelzima, Maisyah Nita Afriani Nofrita Nofrita Novianti, Hera Novita Ariani Noza Hilbertina Noza Hilbertina, Noza Nur Afrinin Syah Nuzulia Irawati O ktora, Meta Zulyati Oktora, Meta Zulyati Putra Santoso Putri Amran, Fajriana Anggun Putri, Biomechy Oktomalio Putri, Nabila Priscilla R. Zuryati Nizar Rahmi Ramadhani Rauza Sukma Rita Restu Susanti Ria Oktavia Ria Oktavia Rina Gustia Rio Hendra Robby Jannatan Rony Rustam Runky Pebranka Rusnita, Dewi RZ Nizar Safnita, Dewi Salmiah Agus Salmiah Agus Salmiah Agus Selfi Renita Rusjdi, Selfi Selly Alinta Syukri Setiawatu, Yessy Sisca Dwi Yarni Siti Nurhajjah SRI LESTARI Sri Lestari Sri Wahyuni Handayani Sri Wahyuni Handayani, Sri Wahyuni Suci Rahmadhani Sukri Rahman Syamel Muhammad Tiffany, Begum Utama, Bobby Indra Yarni, Sisca Dwi Yenita . Yenita Yenita Yenny Raflis Yessy Setiawati Yessy Setiawati Zehan Afifa Yusran Zulfadli Syahrul, Muhammad